Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Barrier Therapeutics grosses $46mm with Series B financing

04 Aug 2014

Executive Summary

Newly formed Barrier Therapeutics (dermatology drug development; Johnson & Johnson spin-out) grossed $46mm with its Series B round private placement to JP Morgan Partners and TL Ventures, both of which served as lead investors, and to Perseus-Soros BioPharmaceutical Fund, Baker/Tisch Investment Partners, and KBC.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By